Jefferies Financial Group Inc. purchased a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 23,428 shares of the company’s stock, valued at approximately $1,625,000. Jefferies Financial Group Inc. owned about 0.08% of Inspire Medical Systems as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Inspire Medical Systems during the second quarter worth about $211,341,000. ADAR1 Capital Management LLC increased its holdings in shares of Inspire Medical Systems by 2,601.3% during the first quarter. ADAR1 Capital Management LLC now owns 405,197 shares of the company’s stock worth $20,900,000 after buying an additional 390,197 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Inspire Medical Systems by 66.2% in the second quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock valued at $38,561,000 after acquiring an additional 344,221 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of Inspire Medical Systems in the second quarter valued at approximately $12,021,235. Finally, Bank of America Corp DE bought a new position in shares of Inspire Medical Systems in the second quarter valued at approximately $11,099,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. increased their price target on Inspire Medical Systems from $60.00 to $65.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. Royal Bank Of Canada lifted their price objective on Inspire Medical Systems from $60.00 to $75.00 and gave the company a “sector perform” rating in a research report on Thursday, October 1st. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Weiss Ratings cut Inspire Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday. Finally, Stifel Nicolaus increased their target price on Inspire Medical Systems from $75.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $71.24.
Check Out Our Latest Analysis on INSP
Inspire Medical Systems Trading Up 0.1%
Shares of INSP stock opened at $61.16 on Monday. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03. The firm’s 50 day moving average is $68.94 and its 200-day moving average is $57.69. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of 17.78, a PEG ratio of 4.47 and a beta of 0.67.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $206.69 million for the quarter, compared to analysts’ expectations of $204.31 million. Inspire Medical Systems had a net margin of 11.43% and a return on equity of 7.32%. Inspire Medical Systems’s revenue was down 7.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.38 earnings per share. On average, equities research analysts forecast that Inspire Medical Systems, Inc. will post 1.29 earnings per share for the current fiscal year.
Inspire Medical Systems Company Profile
Inspire Medical Systems is a medical technology company focused on treatments for obstructive sleep apnea, a condition in which breathing repeatedly stops or becomes restricted during sleep. Founded in 2007 and based in Minnesota, the company develops implantable devices intended for certain patients who cannot use or benefit from conventional positive airway pressure therapy. Its primary product, the Inspire Upper Airway Stimulation system, uses an implanted device to monitor breathing and deliver mild stimulation to the hypoglossal nerve, helping keep the airway open during sleep.
Further Reading
- Five stocks we like better than Inspire Medical Systems
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
